Date:2/14/2013

thcare reform further augmented by restrictive government policies to prioritize the Essential Drug List (EDL) drug sales, which simultaneously reduced the sales of our higher margin generic pharmaceuticals. Our top five product sales are: Gingko mihuan oral liquid (GMOL) for stroke and cardiovascular disorders: $6.5 million; Mycophenolate mofetil capsules (MM) for renal transplant: $2.2 million; Azithromycin tablets (AZI) for infection: $1.0 million; Qingre jiedu oral liquid (QR): $0.8 million and Qianlie Shule capsules (QS) for prostate conditions: $0.38 million. These products totaled $10.9 million in sales, representing 62% of the quarterly revenue. Similar to the first quarter of fiscal 2013, the former two core products Apu Shuangxin (Apu) and Xuelian Chongcao (XLCC) which are not covered by EDL or National Reimbursement List (NRL) lists have not reached the level to be included in the top five products mainly because the healthcare reform regulations favor EDL and NRL drugs. Compared with a year earlier, the total core product sales have risen significantly from $7.5 million for the quarter ended December 31, 2011 mainly due to the significant rise in GMOL sales of 51% year over year from $4.3 million for the quarter ended December 31, 2011. This is attributable to the inclusion of GMOL in Provincial EDL such as the provinces of Henan and Shandong and the City of Chongqing. The contribution from our distribution business through TMT amounted to $4.6 million at 13% gross margin.

Gross Margin for the quarter ended December 31, 2012 was 38.7% as compared to 33.4% for the quarter ended December 31, 2011. Our gross margin improved mainly as a result of a greater mix of higher margin products sold during the period supported by a stabilization of generic pricing pressure. While a trend of continuous margin improvement has not yet been affirmed the present sales data supports a flattening and slightly positive trend in our gross margins.

<
'/>"/>

SOURCE Tianyin Pharmaceutical Co., Inc. Copyright©2012 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11
Related medicine technology :

1. Regeneron Reports Fourth Quarter and Full Year 2012 Financial and Operating Results
2. Hanger Reports $0.62 Diluted EPS for the Fourth Quarter 2012
3. Hospira Reports Fourth-Quarter and Full-Year 2012 Results
4. Cynosure Reports Record Revenues for Fourth-Quarter and Full-Year 2012
5. Vanda Pharmaceuticals Reports Fourth Quarter 2012 and Full Year 2012 Results
6. Landauer, Inc. Reports Fiscal 2013 First Quarter Results
7. Allied Healthcare Products Reports Second Quarter Loss
8. Medical Devices Research: Country Reports on Market Profile, Competitive Environment and more at RnRMarketResearch.com
9. Pharmaceutical Market & Biotechnology Industry 2013 Outlook in New Research Reports at ReportsnReports.com
10. Misonix Reports Financial Results for First Half of Fiscal 2013
11. CareFusion Reports First Half Fiscal 2013 Results